BioNTech SE (BNTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 132.29 |
| Open | 133.00 |
| Bid | 131.67 x 800 |
| Ask | 133.99 x 1400 |
| Day's Range | 129.22 - 134.26 |
| 52 Week Range | 117.08 - 464.00 |
| Volume | |
| Avg. Volume | 1,388,675 |
| Market Cap | 32.507B |
| Beta (5Y Monthly) | -0.70 |
| PE Ratio (TTM) | 4.25 |
| EPS (TTM) | 31.54 |
| Earnings Date | Nov 09, 2021 |
| Forward Dividend & Yield | 2.11 (1.33%) |
| Ex-Dividend Date | Jun 02, 2022 |
| 1y Target Est | 320.42 |
- Reuters
BioNTtech in conflict with regulator over new COVID vaccine approval - WAS
The launch of German drugmaker BioNTech's vaccine adapted to the Omicron coronavirus variant may be delayed due to a disagreement with the regulator over the approval process, the Welt Am Sonntag (WAS) newspaper reported on Saturday. The regulator should still decide by the end of June whether or not to approve the new vaccine but BioNTech Chief Executive Ugur Sahin does not plan to submit any new clinical trials, WAS reported, citing the Financial Times. The reason for this was that the approval "should go through the same regulatory process as ordinary flu vaccines", which would allow the new COVID-19 vaccine to be delivered in three months, WAS cited Sahin as saying.
- The Wall Street Journal
CDC Recommends Moderna’s Covid-19 Vaccine for Kids 6 to 17 Years
The CDC recommended use of Moderna’s Covid-19 vaccine in children 6 to 17 years, the final step in allowing the shots to become widely available.
- MarketWatch
CDC panel backs Moderna vaccine for children aged 6 to 17, and study finds vaccines saved about 20 million lives in their first year
A panel of advisers to the Centers for Disease Control and Prevention voted unanimously Thursday to recommend Moderna's COVID vaccine for children and adolescents aged 6 to 17.
